{"id":407249,"date":"2021-01-04T07:03:26","date_gmt":"2021-01-04T12:03:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=407249"},"modified":"2021-01-04T07:03:26","modified_gmt":"2021-01-04T12:03:26","slug":"caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/","title":{"rendered":"CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance"},"content":{"rendered":"<h2>\nCareDx wins a 2-year competitive tender with the French National Blood Service, \u00c9tablissement Fran\u00e7ais du Sang<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Jan.  04, 2021  (GLOBE NEWSWIRE) &#8212; CareDx, Inc.\u00a0(Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that AlloSeq HCT was selected as the primary solution for chimerism monitoring of stem cell transplant patients by the French National Blood Service, \u00c9tablissement Fran\u00e7ais du Sang (EFS). CareDx won a two-year competitive tender to supply AlloSeq HCT in collaboration with Laboratoires Nephrotek in France.<\/p>\n<p align=\"left\">The EFS supplies cell and tissue therapy solutions to hospitals in France for solid organ and hematopoietic stem-cell transplants. CareDx\u2019s innovative AlloSeq HCT chimerism monitoring solution is the first NGS-based chimerism solution approved by EFS. The France tender was a competitive process, and AlloSeq HCT was selected based on its best-in-class sensitivity and under 24-hour turnaround.<\/p>\n<p align=\"left\">\u201cLaboratoires Nephrotek is very honored to partner with CareDx and to be selected by the EFS to bring AlloSeq HCT and NGS innovation in chimerism monitoring for improved transplant patient care in France,\u201d said Dr. Joseph Coulloc\u2019h, CEO, Laboratoires Nephrotek. \u201cWe look forward to collaborating with the labs and begin the transition process to establish AlloSeq HCT as the leading chimerism testing solution in France.\u201d<\/p>\n<p align=\"left\">\u201cThis success with the EFS tender showcases CareDx\u2019s commitment to innovation for transplant patient care. We are excited to bring our solutions to stem cell transplant patients across France with the new solutions for NGS based chimerism monitoring,\u201d said Reg Seeto, CEO, CareDx.<\/p>\n<p align=\"left\">\n        <strong>About<\/strong><br \/>\n        <strong>\u00a0CareDx<\/strong><br \/>\n        <br \/> CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AalVj_Q_iNyMk7PXbUfsP80xMnbbjLOIcfw7v__QxUyVy1qBifqFOXmvFG5C3fCGI9aXOCEhH4-RoxkNzIKaNQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.CareDx.com<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong>CONTACTS:<\/strong>\n      <\/p>\n<p align=\"left\">CareDx, Inc.<br \/>Sasha King<br \/>Chief Marketing Officer<br \/>415-287-2393<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M_S3yu42B5Dc4BaGiaFNTWV4RxwsXOIg1gLi9F5XtTd7RbxW-UolvNx7sv7WYALnusJy-A43QyZe_KAK4c8JCQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">sking@caredx.com<\/a><\/p>\n<p align=\"left\">Investor Relations<br \/>Greg Chodaczek<br \/> 347-610-7010<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Byzke96I4DWqZhVGmt8JrEM5tybe5jQ3j6N8nKPRr-7ZJo5HxwYSAc4mv2OS65ve3PMuiy15LqfPAh8Pa_MvpkcozYN6J6zigWn7_t1DLhY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investor@caredx.com<\/a><\/u><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NCMzOTAyNTI5IzIwMDQ1MDM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b2ce14cd-ca62-4bb9-8e28-46e728c38385\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CareDx wins a 2-year competitive tender with the French National Blood Service, \u00c9tablissement Fran\u00e7ais du Sang SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; CareDx, Inc.\u00a0(Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that AlloSeq HCT was selected as the primary solution for chimerism monitoring of stem cell transplant patients by the French National Blood Service, \u00c9tablissement Fran\u00e7ais du Sang (EFS). CareDx won a two-year competitive tender to supply AlloSeq HCT in collaboration with Laboratoires Nephrotek in France. The EFS supplies cell and tissue therapy solutions to hospitals in France for solid organ and hematopoietic stem-cell transplants. CareDx\u2019s innovative AlloSeq &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-407249","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CareDx wins a 2-year competitive tender with the French National Blood Service, \u00c9tablissement Fran\u00e7ais du Sang SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; CareDx, Inc.\u00a0(Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that AlloSeq HCT was selected as the primary solution for chimerism monitoring of stem cell transplant patients by the French National Blood Service, \u00c9tablissement Fran\u00e7ais du Sang (EFS). CareDx won a two-year competitive tender to supply AlloSeq HCT in collaboration with Laboratoires Nephrotek in France. The EFS supplies cell and tissue therapy solutions to hospitals in France for solid organ and hematopoietic stem-cell transplants. CareDx\u2019s innovative AlloSeq &hellip; Continue reading &quot;CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-04T12:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NCMzOTAyNTI5IzIwMDQ1MDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance\",\"datePublished\":\"2021-01-04T12:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\\\/\"},\"wordCount\":369,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTc1NCMzOTAyNTI5IzIwMDQ1MDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\\\/\",\"name\":\"CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTc1NCMzOTAyNTI5IzIwMDQ1MDM=\",\"datePublished\":\"2021-01-04T12:03:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTc1NCMzOTAyNTI5IzIwMDQ1MDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTc1NCMzOTAyNTI5IzIwMDQ1MDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/","og_locale":"en_US","og_type":"article","og_title":"CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance - Market Newsdesk","og_description":"CareDx wins a 2-year competitive tender with the French National Blood Service, \u00c9tablissement Fran\u00e7ais du Sang SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; CareDx, Inc.\u00a0(Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that AlloSeq HCT was selected as the primary solution for chimerism monitoring of stem cell transplant patients by the French National Blood Service, \u00c9tablissement Fran\u00e7ais du Sang (EFS). CareDx won a two-year competitive tender to supply AlloSeq HCT in collaboration with Laboratoires Nephrotek in France. The EFS supplies cell and tissue therapy solutions to hospitals in France for solid organ and hematopoietic stem-cell transplants. CareDx\u2019s innovative AlloSeq &hellip; Continue reading \"CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-04T12:03:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NCMzOTAyNTI5IzIwMDQ1MDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance","datePublished":"2021-01-04T12:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/"},"wordCount":369,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NCMzOTAyNTI5IzIwMDQ1MDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/","name":"CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NCMzOTAyNTI5IzIwMDQ1MDM=","datePublished":"2021-01-04T12:03:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NCMzOTAyNTI5IzIwMDQ1MDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTc1NCMzOTAyNTI5IzIwMDQ1MDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredxs-alloseq-hct-wins-tender-for-french-stem-cell-transplant-patient-surveillance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CareDx\u2019s AlloSeq HCT Wins Tender\u00a0for French Stem Cell Transplant Patient Surveillance"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=407249"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407249\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=407249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=407249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=407249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}